rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

GTCB - GTC Biotherapeutics - Deel 12

2.690 Posts
Pagina: «« 1 ... 129 130 131 132 133 ... 135 »» | Laatste | Omlaag ↓
  1. [verwijderd] 22 juli 2009 10:19

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    GTC Biotherapeutics Inc. (GTCB) Corporate Event Announcement Notice

    Tue. July 21, 2009; Posted: 09:07 PM
    GTCBD | Quote | Chart | News | PowerRating -- e>GTC Biotherapeutics Inc. (GTCB)

    Expected next earnings release:
    Announcement date: 7/31/2009 - Before Market
    Earnings Quarter: Q2
    Announcement Status: Unconfirmed

    Expected next split:
    Split Announcement Date: 5/26/2009
    Split Record Date: 5/26/2009
    Stock Split Date: 5/26/2009
    Stock Split Ratio: 1:10

    Unconfirmed

    Slot $ 2,07 nog 7,93 te gaan. ~~)
  2. [verwijderd] 24 juli 2009 08:48

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ludwig mack schreef:

    [quote=StillChill]
    [quote=beur]
    Gelukkkig weer boven de 2!

    2,03 +8.56%
    [/quote]

    Dat zal niet lang meer duren. Er zijn geen believers meer, dit aandeel is zo dood als een pier. Helaas, want ik heb er nog een aantal liggen.
    [/quote]

    verkoop die snel dan: wat weerhoud je dan man,of toch ook een believer?
    verkoop ze dan, ben je van alles af, lucht op joh; doen!
    Gefrustreerd?

    Waarom zou ik ze verkopen, levert niks meer op. Op de plank ermee en kijken waar ze staan als ik met pensioen ga.
  4. ludwig mack 24 juli 2009 10:13

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    quote:

    StillChill schreef:

    [quote=ludwig mack]
    [quote=StillChill]
    [quote=beur]
    Gelukkkig weer boven de 2!

    2,03 +8.56%
    [/quote]

    Dat zal niet lang meer duren. Er zijn geen believers meer, dit aandeel is zo dood als een pier. Helaas, want ik heb er nog een aantal liggen.
    [/quote]

    verkoop die snel dan: wat weerhoud je dan man,of toch ook een believer?
    verkoop ze dan, ben je van alles af, lucht op joh; doen!
    [/quote]

    Gefrustreerd?

    Waarom zou ik ze verkopen, levert niks meer op. Op de plank ermee en kijken waar ze staan als ik met pensioen ga.
    ik gaf je een persoonlijk advies en krijg een trap terug, niet sympa, toch?

    lees je eigen posting waar ik op reageer, en je weet wie er teleurgesteld is.
    zonder geloof, op de plank leggen is ook een escape oplossing, een wegdrukken, een schijnoplossing voor je geest, niet van harte dus, maar evengoed plezier met je belegging .........

    hoe ver is je pensioen ?

    ;-)
  5. [verwijderd] 24 juli 2009 10:40

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    mensen, ludwig: laat je niet meeslepen, schiet niemand iets mee op
    probeer emotie weg te laten tov anderen, is negatieve energie welke je niets oplevert en zeker geen rendement
  7. [verwijderd] 24 juli 2009 11:59

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ludwig mack schreef:

    [quote=StillChill]
    [quote=ludwig mack]
    [quote=StillChill]
    [quote=beur]
    Gelukkkig weer boven de 2!

    2,03 +8.56%
    [/quote]

    Dat zal niet lang meer duren. Er zijn geen believers meer, dit aandeel is zo dood als een pier. Helaas, want ik heb er nog een aantal liggen.
    [/quote]

    verkoop die snel dan: wat weerhoud je dan man,of toch ook een believer?
    verkoop ze dan, ben je van alles af, lucht op joh; doen!
    [/quote]

    Gefrustreerd?

    Waarom zou ik ze verkopen, levert niks meer op. Op de plank ermee en kijken waar ze staan als ik met pensioen ga.
    [/quote]

    ik gaf je een persoonlijk advies en krijg een trap terug, niet sympa, toch?

    lees je eigen posting waar ik op reageer, en je weet wie er teleurgesteld is.
    zonder geloof, op de plank leggen is ook een escape oplossing, een wegdrukken, een schijnoplossing voor je geest, niet van harte dus, maar evengoed plezier met je belegging .........

    hoe ver is je pensioen ?

    ;-)
    Ik heb maar een kleine plukje, zeker na de RS. Ik zit er niet mee, we kijken wel wat er gebeurt.
    Een trap probeerde ik je niet te geven, was meer een vraag omdat ik je reactie wat dwingend/agressief vond overkomen. Waarschijnlijk onterecht, we begrepen elkaar gewoon niet, I guess.

    Het enige waar ik van baal is dat ik niet verkocht heb boven de .90, maar in de tijd dat ik nog een believer was na de goedkeuring zag ik dit waardeloze aandeel door een roze bril. 1 dollar moest het toch halen, not.

    Op de plank liggen ze prima, natuurlijk een noodoplossing, maar in mijn ogen de enige mogelijkheid om nog iets van mn fout te maken.

    Mn pensioen is over een jaar of 40, tel dr gerust nog 5 bovenop omdat de pensioenfondsen net als ik niet kunnen beleggen.
  13. welshterrier 5 25 juli 2009 10:11

    • welshterrier 5

      Lid sinds: 23 mrt 2004

      Laatste bezoek: 26 mrt 2025

    • Aanbevelingen

      Ontvangen: 291

      Gegeven: 1101

    •    Aantal posts: 20.113

    , JULY 31, 2009

    Framingham, Mass., July 24, 2009-- GTC Biotherapeutics, Inc. (Nasdaq: GTCB) (“GTC”) announced today that its financial results for the second quarter 2009 will be released on Friday, July 31, 2009 followed by a webcast conference call starting at 10:00 a.m. Eastern Time. You may access the live internet broadcast or the subsequent archived recording, on GTC’s website at www.gtc-bio.com or access the conference call as follows:



    Live Call – In the United States, dial 1-877-407-0778

    Outside the United States, dial 201-689-8565



    Audio Archive – In the United States, dial 1-877-660-6853

    Outside the United States, dial 201-612-7415
    Reference call ID: Account #: 286 Conference ID #: 328989



    NOTE: a replay of the call will be available one hour following the end of the call and will be accessible until August 12, 2009 at 11:59 PM.

  14. [verwijderd] 31 juli 2009 14:07

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    GTC Biotherapeutics Reports Second Quarter 2009 Financial Results

    finance.yahoo.com/news/GTC-Biotherape...

    FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc.'s ("GTC", Nasdaq: GTCB) total net loss for the second quarter ended June 28, 2009, was $10.8 million, or $1.03 per share, compared to $2.2 million, or $0.22 per share, for the second quarter of 2008. The total net loss for the first six months of 2009 was $21.1 million, or $2.03 per share, compared to $10.4 million, or $1.12 per share, for the first six months of 2008. The first half of 2008 included significant sales of ATryn® to our former partner in Europe, LEO Pharma A/S. While revenues for the first six months of 2009 were approximately $0.9 million, during that same period there were $5.7 million of milestones received that were not recognized as revenue and were recorded as deferred revenue on the balance sheet. Subsequent to yesterday’s special shareholder vote, GTC is receiving $8.3 million of additional funding from LFB Biotechnologies upon the first closing under the June 18, 2009 agreement for the sale of new convertible preferred stock.

    “As a result of our financing transaction with our strategic partner, LFB Biotechnologies, we are taking an important step in re-establishing the financial stability of GTC with a committed, long term investor,” stated Geoffrey F. Cox, Ph.D., GTC’s Chairman of the Board and Chief Executive Officer. “We have also been very encouraged by the strong launch of ATryn® by our partner, Lundbeck Inc., and we believe this bodes well for future sales in the U.S. in the approved hereditary antithrombin deficiency indication as well as the potential for future broader indications we are developing together for approval, such as heparin resistance.”

    ATryn® Update

    In the first quarter of 2009, GTC obtained approval of the Biologics License Application (BLA) for ATryn®, a recombinant form of human antithrombin, for the prophylactic treatment of hereditary antithrombin deficient patients undergoing surgery or childbirth. Lundbeck Inc. launched the product in the U.S. in the second quarter of 2009. GTC and Lundbeck Inc. are now engaged in discussions with the U.S. Food and Drug Administration on development plans for ATryn® as a treatment for heparin resistance during cardiopulmonary bypass surgery.
  16. ludwig mack 31 juli 2009 18:32

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    GTC Biotherapeutics Inc(NasdaqCM: GTCB)
    Real-Time: 2.02 0.19 (8.60%) 11:08am EThelp
    Last Trade: 2.01
    Trade Time: 12:09pm ET
    Change: 0.20 (9.05%)
    Prev Close: 2.21
    Open: 2.18
    Bid: 2.01 x 400
    Ask: 2.02 x 100
    1y Target Est: 0.75
    Day's Range: 1.98 - 2.21
    52wk Range: 0.33 - 9.50
    Volume: 47,425
    Avg Vol (3m): 42,860.9
    Market Cap: 20.98M
    P/E (ttm): N/A
    EPS (ttm): -2.40
    Div & Yield: N/A (N/A

    niet goed ontvangen: de cijfers waren bekend toen de beurs opende, dus ............, en toch range 1,98 - 2,21;

    vond sterk dat cox projecties voor verkoop usa erg belovend vond, maar er verder geen inhoud aan gaf is dan jammer ...........
  18. [verwijderd] 31 juli 2009 19:13

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ludwig mack schreef:

    GTC Biotherapeutics Inc(NasdaqCM: GTCB)
    Real-Time: 2.02 0.19 (8.60%) 11:08am EThelp
    Last Trade: 2.01
    Trade Time: 12:09pm ET
    Change: 0.20 (9.05%)
    Prev Close: 2.21
    Open: 2.18
    Bid: 2.01 x 400
    Ask: 2.02 x 100
    1y Target Est: 0.75
    Day's Range: 1.98 - 2.21
    52wk Range: 0.33 - 9.50
    Volume: 47,425
    Avg Vol (3m): 42,860.9
    Market Cap: 20.98M
    P/E (ttm): N/A
    EPS (ttm): -2.40
    Div & Yield: N/A (N/A

    niet goed ontvangen: de cijfers waren bekend toen de beurs opende, dus ............, en toch range 1,98 - 2,21;

    vond sterk dat cox projecties voor verkoop usa erg belovend vond, maar er verder geen inhoud aan gaf is dan jammer ...........
    Wie is Cox?

    Wat een drama, was te verwachten, geen omzet maar een cost-cut dat zelfs lukt niet.

    Een net loss van 10 miljoen, als dat geen milestone is?

    houd maar op GTCB.

    Jammer, ik had het ook graag anders gezien.

    ex-aandeelhouder.

  19. [verwijderd] 31 juli 2009 19:14

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Heb nog niet kunnen luisteren naar de CC. De cijfers worden in ieder geval minder goed ontvangen en dat is niet zo vreemd wanneer je een snelle vergelijking maakt met 2008.

    Hieronder het verslag van een recente presentatie van Atryn-studies ten overstaan van de Jaarvergadering van de International Society on Thrombosis and Haemostasis (ISTH) in Boston op 15 en 16 juli j.l.

    www.lundbeckinc.com/USA/media/press-r...

    Data Show ATryn® Effectively Prevents Serious Blood Clots in Patients with Hereditary Antithrombin Deficiency

    Dosing Algorithms Allow for Normalization of Antithrombin Levels During Specific High-Risk Situations

    BOSTON, Mass., July 16, 2009 – Data presented at the annual meeting of the International Society on Thrombosis and Haemostasis (ISTH) in Boston show that ATryn® (Antithrombin [Recombinant]) safely prevents peri-operative and peri-partum acute deep vein thrombosis (DVT) or other venous thromboembolic events in patients with hereditary antithrombin deficiency (HD AT).1 ATryn is not indicated for treatment of thromboembolic events in HD AT patients. Additionally, data validate dosing algorithms that, along with AT activity monitoring, allows physicians to normalize antithrombin levels during the high-risk situations of surgery and childbirth.2

    "ATryn provides physicians with a safe and effective new treatment option for restoring and maintaining antithrombin levels,"1,2 said study co-investigator Michael Paidas, M.D., associate professor and director, Yale Women and Children's Center for Blood Disorders. "This is important because these patients have a very high risk of venous thromboembolism that can lead to serious and potentially life threatening complications."3

    Antithrombin is a naturally occurring protein that helps regulate the blood clotting mechanism in the body. People with HD AT have reduced antithrombin activity, putting them at increased risk for venous thromboembolic events (VTE), including pulmonary embolism and DVT.3 These patients are at particular risk during surgery and childbirth procedures, when antithrombin levels are often low and need to be carefully managed.

    "Data presented show that these validated, individualized dosing algorithms can be used in these different HD AT patient populations, which allows physicians to adjust antithrombin levels based on the fluctuating needs," said Dr. Paidas.2

    ATryn was created to provide a safe and reliable supply of recombinant antithrombin.4 Approved by the U.S. Food and Drug Administration (FDA) in February 2009 for the prevention of peri-operative and peri-partum thromboembolic events in patients with HD AT,5 it is the only recombinant form of antithrombin available in the world.6 Prior to the availability of ATryn, HD AT patients undergoing surgery or giving birth requiring an antithrombin therapy received treatment derived from human plasma.4 ATryn is not formulated with human plasma proteins.5

    Efficacy and Safety Results (Abstract PP-WE-405; Presented July 15, 2009)

    The first poster provided a pooled analysis of two Phase III studies (N=32) evaluating the efficacy and safety of ATryn in patients with HD AT undergoing surgery (11 patients) or childbirth procedures (21 patients). Patients were administered ATryn intravenously to maintain antithrombin activity within normal range (80-120%). The incidence of acute DVT or other venous thromboembolic events was assessed within seven days of treatment discontinuation. Safety was based on adverse events and laboratory evaluations.

    One patient had an asymptomatic, acute DVT that was seen on duplex ultrasound. No other patients had a confirmed thromboembolism up to seven days after cessation of treatment with ATryn. Of note, one patient was diagnosed with DVT 10 days after cessation of ATryn treatment and one patient was diagnosed with pulmonary embolism 14 days after finishing ATryn treatment, which reflect the high risk of VTE in HD AT patients and the need for sufficient follow-up anticoagulation.

    The first poster also included a safety analysis which involved 47 patients from three studies (including a pharmacokinetic study). Adverse events were reported in 72 percent of patients and reflect those typically anticipated during the peri-partum and peri-operative period. Fifteen percent of patients reported an adverse event that was thought to be possibly related to ATryn, but none of these led to withdrawal from the study. Significant hemorrhage was reported in three patients: two of these episodes were associated with excessive heparin levels at the time of hemorrhage. The most commonly reported adverse events were anemia, vomiting, and headache (each 10.6%).1

    Dosing Algorithm Results (Abstract PP-TH-414; Presented July 16, 2009)

    The second poster described the development and validation of a dosing algorithm using these two Phase III studies to help physicians maintain optimal levels of antithrombin in HD AT patients during high-risk surgical and childbirth procedures.

    The analysis of AT levels from the first Phase III study (N=14: 9 pregnant and 5 surgical patients) that used the same dosing algorithm for pregnant and surgical patients found that pregnant HD AT patients have a higher clearance and volume of distribution than surgical patients, which led to the development of a specific dosing algorithm for pregnant patients.

    The second study (N=18: 12 pregnant and 6 surgical) used a dosing formula based on patient type (pregnant or surgical) and, in most patients, AT level normalization markedly improved. Overall, a median of only one (range 0-6) infusion rate adjustment per patient was needed during treatment of a median of 3.2 days (range 0.9 – 14).2

    These studies support the use of separate dosing algorithms for pregnant and surgical patients.


  21. [verwijderd] 31 juli 2009 19:40

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    En eentje die ik al beknopt eerder gemeld heb in mei:

    www.rarediseases.org/news/Pioneers

    NORD Honored Rare Disease Pioneers

    DANBURY, CT (May 11, 2009)-----The National Organization for Rare Disorders (NORD) honored a senior U.S. Senator, a top Administration official, a cutting-edge television network, and several pioneering companies developing treatments for rare diseases at the 2009 NORD Gala at the National Press Club in Washington, DC, on Thursday, May 14.

    The NORD Gala is an annual event at which researchers and others are honored for significant achievements to improve the lives of people with rare diseases. NORD represents the nearly 30 million Americans who have rare diseases.

    "We are honored to have this opportunity to pay tribute to pioneers in public policy, the sciences, and health-related education and awareness," NORD President and CEO Peter L. Saltonstall said. "These individuals and companies have demonstrated compassion and concern for what was once a forgotten community—people who have diseases affecting small patient populations. We are happy to honor them for accomplishments that have literally saved lives."

    In the United States, a disease is considered rare if it affects fewer than 200,000 Americans. According to the National Institutes of Health (NIH), there are between 6,000 and 7,000 such diseases affecting nearly 30 million Americans. Many rare diseases are serious, life-threatening and chronic.

    The 2009 NORD Gala honorees are:

    Senator Edward Kennedy for lifetime achievement in health promotion leadership and for specific accomplishments on behalf of populations that are underserved by our nation’s healthcare system
    Social Security Commissioner Michael J. Astrue, J.D., for his focus on reducing the disability backlog and improving service to the public
    Discovery Health, for educational programming that helps the public understand problems such as difficulty getting an accurate diagnosis that accompany having a rare disease
    John I. Gallin, M.D., Director of the National Institutes of Health Clinical Center, for contributions as an excellent administrator, a caring physician, and a pioneering researcher
    Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, for developing and bringing to market Nexavar®, a treatment option for patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable
    Baxter International Inc. for developing Ceprotin® for patients with life-threatening blood-clotting complications related to severe congenital protein C deficiency
    BioMarin Pharmaceutical, Inc. for developing Kuvan®, the first specific drug therapy for phenylketonuria (PKU)
    Biovail Corporation, for making available to the patient community Xenazine®, the first treatment to be approved by the Food and Drug Administration (FDA) for the jerky movements (chorea) associated with Huntington’s disease
    CSL Behring, for developing and bringing to market RiaSTAP™, the first and only treatment for acute bleeding episodes in patients with congenital fibrinogen deficiency, an extremely rare, potentially life-threatening bleeding disorder
    Eisai Inc. for bringing to the patient community Banzel™, a much-needed treatment alternative for seizures linked to Lennox-Gastaut syndrome, a severe form of childhood epilepsy
    GTC Biotherapeutics, Inc. for developing ATryn®, an anticoagulant to prevent blood clots in people with a rare disease known as hereditary antithrombin (AT) deficiency
    Regeneron Pharmaceuticals, Inc. for developing Arcalyst®, the only approved treatment for people with a recently identified group of rare, inherited, autoinflammatory disorders known as CAPS
    Talecris Biotherapeutics, Inc. for developing Gamunex®, the first therapy approved for treating people with chronic inflammatory demyelinating polyneuropathy
    ViroPharma, Inc. for making available to patients Cinryze®, the first drug approved by FDA to prevent swelling that occurs in various body systems as a result of a disease known as hereditary angioedema (HAE)

2.690 Posts
Pagina: «« 1 ... 129 130 131 132 133 ... 135 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.124
AB InBev 2 5.538
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.217
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.878
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.848
Aedifica 3 926
Aegon 3.258 323.086
AFC Ajax 538 7.092
Affimed NV 2 6.305
ageas 5.844 109.906
Agfa-Gevaert 14 2.063
Ahold 3.538 74.353
Air France - KLM 1.025 35.295
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.051
Alfen 16 25.312
Allfunds Group 4 1.517
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 425
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.963
AMG 971 134.460
AMS 3 73
Amsterdam Commodities 305 6.745
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 496
Antonov 22.632 153.605
Aperam 92 15.063
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.807
Arcelor Mittal 2.034 320.999
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.355
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.623
ASML 1.766 110.343
ASR Nederland 21 4.513
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.959
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449